Dr. Sersch, M.D., Ph.D. has over 25 years of academia and industry experience, including extensive experience in cell and gene therapy, immuno-oncology, mAb and small molecules in both multi-national and biotechnology companies. Prior to joining Gracell as our Chief Medical Officer in 2020, Dr. Sersch served as Chief Medical Officer at a Nasdaq-listed CAR-T cell and gene therapy company where she led the clinical development of rare diseases, hematological malignancies, and solid tumors indications, including the successful IND filing and approval of a CAR-T cell therapy in AML, BPDCN and Myelodysplastic syndrome. Prior to that, Dr. Sersch served as Executive Medical Director at Amgen Inc. leading the early and late stage clinical development for hematological malignancies. At Amgen, Dr. Sersch successfully led global filing activities for a multiple myeloma drug within the FDA’s novel rolling submission program. Prior to joining Amgen, Dr. Sersch served as a Senior Medical Director at Roche/Genentech in different capacities with increasing responsibilities leading the global and regional clinical development activities including USA, Europe and Asia, as well as biologics strategy leader for the APAC region. Dr. Sersch successfully led global development and filing activities for mAb therapies. Dr. Sersch holds an M.D. and doctorate degree from the University of Heidelberg in Germany.